Ritonavir

1 Indications and usage norvir: tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. NORVIR tablets are HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection ( 1 ) NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection ( 1 )

12.1 Mechanism of Action Ritonavir is an antiretroviral drug . As an active cytochrome p450 3a inhibitor moiety (AbbVie Inc.), Ritonavir modulates physiological signaling proportional to 100 mg/1 Tablet, Film Coated exposure and hepatorenal clearance (SPL 2026-07-23).

Following administration (100 mg/1 Tablet, Film Coated), Ritonavir achieves Approximately 71% to 83% enteral uptake across labeled Ritonavir strengths bioavailability and maximum serum exposure occurs 2–4 hours after ritonavir dosing onset, governed by a Steady-state plasma equilibrium reached over 3–11 hour t½ intervals for Ritonavir terminal half-life through predominantly hepatic biotransformation with renal elimination of polar ritonavir conjugates.

Before initiating Ritonavir at 100 mg/1 Tablet, Film Coated, clinical safety checklists rule out 4 contraindications; consult the prescribing information of the co-administered protease inhibitor for contraindication information for that product.; norvir is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (ten) or stevens-johnson syndrome) to ritonavir or any of its ingredients.. Logged tolerability patterns center on nausea (8.4% of reports), headache (7% of reports), fatigue (5.4% of reports).